NCT07171723CompletedEarly phase 1
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment
Effects of Antagonizing the Ghrelin Receptor in Individuals With Obesity on Treatment With Semaglutide
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
This clinical study investigates how blocking the hunger-related ghrelin receptor affects appetite and metabolism in individuals with obesity who are treated with semaglutide (a GLP-1 receptor agonist). LEAP2, a naturally occurring hormone that inhibits the ghrelin receptor, is used as the investigational compound. The objective of the study is to clarify how the ghrelin system functions when appetite is suppressed by semaglutide treatment. Participants will receive either LEAP2 or placebo during two experimental visits in a randomized, double-blind, crossover design. The investigators will assess food intake, appetite sensations, glucose metabolism, and hormonal responses. By examining the interaction between semaglutide and ghrelin signaling, the study aims to improve understanding of how multiple appetite-regulating systems interact and whether additional hunger signals remain active during GLP-1 treatment. The findings may inform the development of future treatments for individuals with obesity.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 8 Sept 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 12 Aug 2026
- Lead sponsor
- University Hospital, Gentofte, Copenhagen
- Diseases
- Obesity
- NCT number
- NCT07171723
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 24
- From 1 Sept 2025 to the primary completion date, 12 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any ongoing medication that investigator evaluates would interfere with study participation
Other illness
- History of hepatobiliary and/or gastrointestinal disorder
- Any physical or psychological condition that investigators evaluate would interfere with study participation including any acute or chronic illnesses.
Lab values
- Kidney disease (serum creatinine above normal range and/or urine albumin-creatinine ratio 30mg/g confirmed with two measurements)
- Glycated haemoglobin HbA1c \> 48 and/or type 1 or type 2 diabetes medical treatment
Other
- Anaemia
- Alanine aminotransferase (ALAT) \> 2 times normal value
- Regular tobacco smoking and/or use of other nicotine products
- Women of childbearing potential who are not using effective contraception
- Pregnancy or breastfeeding
Who the study is looking for
- Age between 18 and 65 years old
- Body mass index (BMI) above ≥ 25 kg/m2
- Ongoing semaglutide treatment with a stable dose of ≥ 1 mg once weekly for a minimum of 3 months prior to inclusion
- Weight stability, defined as a maximum variation of ±3% between the highest and lowest recorded body weight during the 3 months prior to inclusion.
- Informed oral and written consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Clinical Metabolic Research, Gentofte Hospital Coordinator of this site? Confirm its status | Hellerup | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.